This event has already taken place.
Following events might interest you:
Apr 29, 2019 18th European VitreoRetinal Training School 2019
May 04, 2019 SPECTRALIS Ärzte Kurs - Glaukom (SAK-G)
May 10, 2019 Heidelberger Kompetenztage Auge
May 11, 2019 125rd SFO Congress
May 15, 2019 ERG – Grundlagen, Indikation, Auswertung und Fallbeispiele

42nd Annual Macula Society Meeting

FL 34134 Bonita Springs, USA
Congress

42nd Annual Macula Society Meeting

An event for ophthalmologists

Date:
Feb 13, 2019 - Feb 16, 2019, 13:00
Scientific Organization:
The Macula Society
Summary:
42nd Annual Macula Society Meeting 2019 will be held in Bonita Springs, Florida, USA. The meeting is open to members, their guests, co-authors and supporting company representatives. Further information will follow soon.
Credits: 

physicians / medical specialists

max. no. of participants: unlimited
Min fee: k.A.

residents in training

max. no. of participants: unlimited
Min fee: k.A.

for Speakers

Subject of Abstract: Jan 01, 1970
Mind:

Comment:
This event takes place annually and offers the opportunity for continued medical education for physicians / medical specialists and residents in training.
Eventnumber: 25802
Min fee:
 
Places available: unlimited
Language: Englisch
 
Subject of Abstract:
Jan 01, 1970
Published program by the organizer:
Wednesday, February 13, 2019 SESSION I - Diabetic Retinopathy  
     
4:25 p.m Multiethnic Genome-Wide Association Study of Diabetic Retinopathy Lucia Sobrin
4:29 p.m DRGen Study: Novel Genetic Variants in Extreme and Advanced (Proliferative)
Phenotypes of Diabetic Retinopathy
Arup Das
4:33 p.m. Risk Factors for Blindness in Patients With Diabetic Retinopathy: Lessons from
the AAO IRIS® Registry
Rahul Khurana
4:37 p.m. Integrating Diabetic Eye Screening in a Haemodialysis Clinic Tunde Peto
4:41 p.m. Discussion of Previous Four Papers  
4:45 p.m. Is Cataract Surgery a Risk Factor for the Incidence and Progression of Age-Related
Macular Degeneration and Diabetic Retinopathy?
Tien Wong
4:54 p.m Diabetic Retinopathy Outcomes in Untreated Fellow Eyes of Patients Receiving
Ranibizumab in the RIDE/RISE Trials: The Road Less Traveled
Sophie Bakri
5:03 p.m. Patients Ultra-Responsive to Ranibizumab: Rates of >=4-Step Improvement in
Diabetic Retinopathy Severity in DRCR.net Protocol S
Sunir Garg
5:12 p.m. Treatment of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy
with Intravitreal Aflibercept Injection: Results from the Phase 3 PANORAMA Study
David Brown
5:21 p.m. Optical Coherence Tomography Angiography Confirms that Intravitreal Anti-Vascular
Endothelial Growth Factor Can Diminish Signs of Diabetic Retinopathy Without
Reducing Non-Perfusion
Ramin Tadayoni
5:30 p.m Post Hoc Exploratory Analysis of Humphrey Visual Field Changes Through Five
Years in Eyes with Proliferative Diabetic Retinopathy
Michael Elman
5:39 p.m Anti-Vascular Endothelial Growth Factor Therapy and Risk of Traction Retinal
Detachment in Eyes with Proliferative Diabetic Retinopathy: Post Hoc Analysis
of Five DRCR.net Randomized Clinical Trials
Justin Gottlieb
5:50 p.m. Introduction and Presentation of the Lawrence J. Singerman Medal
– Morton F. Goldberg, MD, FACS
 
5:53 p.m. Award Recipient – Matthew D. Davis, MD (posthumous)  
     
  SESSION II - Oncology 1  
     
6:00 p.m. Intravitreal and Intra-Arterial Chemotherapy Drug Discovery Using a
Rabbit Model: Toxicity and Efficacy of Novel Compounds in Vivo
Anthony Daniels
6:04 p.m. Impact of Quantitative Genetic Ancestry on Precision Medicine in Uveal Melanoma J. William Harbour
6:08 p.m. Discussion of Previous Two Papers  
     
  SESSION III - Imaging  
     
6:15 p.m Ultra-Widefield Swept-Source OCT Imaging of Posterior Vitreous in Eyes with
High Myopia
Kyoko Ohno-Matsui
6:24 p.m. Macular Pigment in Multiple Sclerosis Giovanni Staurenghi
6:33 p.m Quantifying Organelles Serving as Signal Sources for Imaging of the Human
Retinal Pigment Epithelium (RPE), via Volume Electron Microscopy
Christine Curcio
6:42 p.m Hyperspectral Autofluorescence (AF) Imaging for Detection of Drusen and
Sub Retinal Pigment Epithelium (subRPE) deposits
R. Theodore Smith
6:46 p.m. Age-Related Changes in Autofluorescent (AF) Granules Accumulation of
the Human Retinal Pigment Epithelium (RPE)
Thomas Ach
6:50 p.m. Diabetic Retinopathy Severity Level Assessment: Comparison of Seven-field
Fundus Photographs to Ultrawide-Field Imaging
Barbara Blodi
6:54 p.m. Quantitative Comparison of Retinal Pixel Area Imaged by Ultra-Wide
Field Fundus Cameras
Ajay Kuriyan
6:58 p.m. Retinal Vascular Geometry and the Subsequent Risk of Diabetes Gavin Tan
7:02 p.m. Discussion of Previous Five Papers  
7:07 p.m. Computational Fluid Dynamics Modeling of Diabetic Microaneurysms Identifies
Blood Flow Parameters Associated with Clot Presence and Local Neural
Retinal Disorganization
Jennifer Sun
7:16 p.m. Topographic Variations of Choroidal Thickness in Healthy Eyes on Swept Source
Optical Coherence Tomography
Alain Gaudric
7:20 p.m. Remodeling of Macular Vortex Veins in Pachychoroid Neovasculopathy Shoji Kishi
7:24 p.m.  Dynamic Changes in Choroidal Conditions During Anti-Vascular Endothelial
Growth Factor Therapy in Polypoidal Choroidal Vasculopathy
Yoko Ozawa
7:28 p.m. Discussion of Previous Three Papers  
     
7:32 p.m. Adjourn  
     
Thursday, February 14, 2019 SESSION IV - OCT Angiography  
     
7:30 a.m. Longitudinal Analaysis of Foveal Microvasculature Using OCT Angiography after
Rhegmatogenous Retinal Detachment Surgery
Seung-Young Yu
7:39 a.m. How Abnormal is this FAZ? - Easier Detection of Diabetic FAZ Enlargement
Comparing En Face OCT Vascular Patterns to OCT Angiography
Richard Rosen
7:46 a.m. Quantitative OCT Angiography Analysis for Classification and Staging of
Non-Proliferative Diabetic Retinopathy
Jennifer Lim
7:53 a.m. Discussion of Previous Two Papers  
7:57 a.m. 4D OCTA: Time-Resolved OCTA Can Visualize Chorioretinal Hemodynamics Nadia Waheed
8:06 a.m. Choriocapillaris Flow Impairment Surrounding Geographic Atrophy Correlates
with Disease Progression
SriniVas Sadda
8:13 a.m Relationship Between Choriocapillaris Flow Deficits Around Geographic
Atrophy and Enlargement Rates Based on Swept Source OCT Imaging
Philip Rosenfeld
8:20 a.m. Discussion of Previous Two Papers  
8:24 a.m. New Proposal for the Pathophysiology of Type 3 Neovascularization as
Based on Multimodal Imaging Findings
Richard Spaide
8:33 a.m Sensitivity of OCT Angiography in the Detection of Choroidal Neovascularization
in Wet AMD in Relation to Anatomical Features on SDOCT
Aude Ambresin
8:37 a.m. 3D Volumetric Analysis of Pigment Epithelial Detachment Progression in
Neovascular AMD using En Face OCT Angiography
David Sarraf
8:44 a.m. Volume-Rendered Projection-Resolved OCT Angiography: 3D Lesion Complexity Is
Associated With Therapy Response in Wet Age-Related Macular Degeneration
Amani Fawzi
8:51 a.m. Discussion of Previous Three Papers  
8:55 a.m. Introduction and Presentation of the Young Investigator Lecture and Award
– Eric H. Souied, MD, PhD
 
8:58 a.m. Award Recipient and Lecture – Giuseppe Querques, MD, PhD  
9:01 a.m. Discussion and Questions  
     
  SESSION V - Neovascular AMD I  
     
9:15 a.m. Prospective Trial Comparing Intravitreal Aflibercept Injection (IAI) Using a Modified
Treat-and-Extend (T&E) to Fixed Bi-Monthly Protocol for PCV: 6-Month Outcomes
Gemmy Cheung
9:24 a.m. Ten-Year Treatment Outcome of Polypoidal Choroidal Vasculopathy Using
Photodynamic Therapy and Anti-Vascular Endothelial Growth Factor
Won Ki Lee
9:33 a.m. A Cost-Utility/Cost-Benefit Analysis of Bevacizumab, Ranibizumab & Aflibercept
Monotherapy for Treating Neovascular Age-Related Macular Degeneration (NVAMD)
Gary Brown
9:37 a.m. Association Between Early Vision-Related Quality of Life Outcomes and Anatomic
Dryness Response in Neovascular Age-Related Macular Degeneration (nAMD):
A Post-Hoc Analysis of VIEW Trials
Michael Singer
9:41 a.m Higher-Order Optical Coherence Tomography (OCT) Fluid Burden Assessment: Analysis
From OSPREY Matched Phase
Justis Ehlers
9:45 a.m. Discussion of Previous Three Papers  
9:48 a.m. Intravitreal Aflibercept in a Routine Treat and Extend Regimen in Treatment-Naïve Wet
AMD Patients: Prefinal 1-Year Outcome Data of the ASTERIA Study
Stephan Michels
9:57 a.m.  Brolucizumab Versus Aflibercept for Neovascular AMD: 48-Week Expanded Fluid
Analyses from the HAWK and HARRIER Studies
Peter Kaiser
10:06 a.m Intravitreal (IVT) Delivery of a Novel Depot Formulation of Sunitinib (GB-102) in
Patients With nAMD: Results of a Phase 1 First-in-Human Study
Pravin Dugel
10:15 a.m. Port Delivery System With Ranibizumab (PDS) in Neovascular AMD: How Ladder
Phase 2 Results Informed Archway Phase 3 Design
Dennis Marcus
10:24 a.m. Phase I/II Randomized Study of Proton Beam with Anti-VEGF For Exudative
Age-Related Macular Degeneration: Long-Term Results
Susanna Park
     
10:30 a.m. Break  
     
  SESSION VI - Deep Learning / Artificial Intelligence  
     
10:50 a.m.  Deep Learning Predicts OCT Measures of Diabetic Macular Thickening From Color
Fundus Photographs
Anthony Adamis
10:59 a.m. Deep Generative Models Creating High-Resolution Synthetic Retinal Images and
Relevance to Humans and Machines
Neil M. Bressler,
11:08 a.m. DeepSeeNet: A Deep Learning Model for Automated Classification of Patient-Based
Age-Related Macular Degeneration Severity from Color Fundus Photographs.
Emily Chew
11:17 a.m. Deep Learning in the Prediction of AMD Disease Progression Ursula Schmidt-Erfurth
11:26 a.m. Automated Segmentation of Lesions in Neovascular AMD Hyung Chan Kim
11:30 a.m. Prognostic Factors in Patients with Neovascular AMD or PCV from Clinical and OCT
Parameters using a Convolutional Neural Network
Hyewon Chung
11:34 a.m.  Artificial Intelligence for Morphology-Based Function Prediction in Neovascular
Age-Related Macular Degeneration
Steffen Schmitz-Valckenberg
11:38 a.m. Robustness of an Autonomous AI System for Detection of Diabetic Retinopathy Michael Abramoff
11:42 a.m. Artificial Intelligence Deep Learning System for Measurement of Retinal
Vascular Caliber
Carol Cheung
11:46 a.m Discussion of Previous Five Papers  
11:50 a.m. Introduction and Presentation of the J. Donald M. Gass Medal – Carol L. Shields,
MD, and Emily Y. Chew, MD
 
11:53 a.m. Anthony AdamisAward Recipient – Usha Chakravarthy, MBBS, MD, PhD  
     
  SESSION VII - Dry AMD  
     
12:00 p.m. Longitudinal Changes in Rod Function in Intermediate Age-Related Macular
Degeneration With and Without Reticular Pseudodrusen
Chi Luu
12:04 p.m. Classification of Intermediate Age-Related Macular Degeneration by Short-Term
Risk for Atrophy on Spectral Domain Optical Coherence Tomography
Eleonora Lad
12:08 p.m. The 9-Step Minnesota Grading System: A Model to Study Disease Pathogenesis Timothy Olsen
12:12 p.m. Müller Cells and Choriocapillaris in the Pathogenesis of Geographic Atrophy
Secondary to Age-Related Macular Degeneration
Elisabetta Pilotto
12:16 p.m. Taurocholic Acid Protects Against Age-Related Macular Degeneration in In Vitro Models Milam Brantley
12:20 p.m. Discussion of Previous Five Papers  
12:25 p.m. Choroidal Vascular Changes in Atrophic AMD: Relationship with Disease
Stage and ARMS2 Genotype
Robert Mullins
12:34 p.m. Kamuvudines for Geographic Atrophy Jayakrishna Ambati
12:43 p.m. The Fate and Prognostic Implications of Cholesterol Crystals in Non-Neovascular
Age-Related Macular Degeneration
K. Bailey Freund
12:52 p.m. Cuticular Drusen: The Nature of Phenotype 3 Lawrence Yannuzzi
1:01 p.m. Subthreshold Nanosecond Laser to Slow Progression of Intermediate Age-Related
Macular Degeneration: The LEAD Trial Secondary Outcomes
Robyn Guymer
1:10 p.m. Photovoltaic Restoration of Central Vision in Patients with Geographic Atrophy José-Alain Sahel
     
1:15 p.m Young Member Mentor Lecture Program  
     
Friday, February 15, 2019    
     
7:00 a.m. Business Meeting  
     
  SESSION VIII - Neovascular AMD II  
     
7:50 a.m. Topical Inhibition of Runx1 Reduces Choroidal Neovascularization in Mice Leo Kim
7:54 a.m. Anti-VEGF Monotherapy for Thick Submacular Hemorrhage Associated with Retinal
Pigment Epithelial Detachment in Age-Related Macular Degeneration
Jeffrey Gross
7:58 a.m. Time to Maximum Response in Eyes with Neovascular AMD Treated with Ranibizumab Demetrios Vavvas
8:02 a.m. Comparison of Intravitreal Silicone Oil Microdroplet Following Multiple Bevacizumab,
Ranibizumab and Aflibercept Injections
John Thompson
8:06 a.m Discussion of Previous Four Papers  
8:10 a.m Antagonism of Mineralocorticoids Inhibits Choroidal Neovascularization: Implication
for Wet AMD
Francine Behar-Cohen
8:19 a.m Human Plasma Metabolomics in Age-Related Macular Degeneration
– Meta-Analysis of Two Distinct Cohorts
Joan Miller
8:28 a.m. Is Drier Really Better in Neovascular Age-Related Macular Degeneration? Nancy Holekamp
8:37 a.m A “Real World” Analysis of Visual Acuity Outcomes in 49,485 Eyes Receiving
Anti-Vascular Endothelial Growth Factor Therapy for Neovascular AMD
Thomas Ciulla
8:46 a.m Real-World Analysis of Injection Frequency Following Wet AMD Diagnosis
According to Baseline Visual Acuity
Judy Kim
8:55 a.m. Analysis of Anti-VEGF Injection Claims Data in Medicare Beneficiaries Following CATT Trial Paul Sternberg, Jr
     
  SESSION IX - Vitreo-Retinal Surgery  
     
9:05 a.m. Central Retinal Artery Occlusion on Postoperative Day One after Vitreoretinal Surgery Harry Flynn
9:09 a.m. Rotation in Retinal Nerve Fiber Layer Peak after Epiretinal Membrane Removal Hyeong Gon Yu
9:13 a.m. Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study:
Five-Year Findings
Stephen Kim
9:17 a.m. Posterior Vitreous Mobility Delineated by Tracking of Optical Coherence
Tomography Images in Eyes with Macular Holes
Keisuke Mori
9:21 a.m. Clinical Characteristics, Risk Factors, and Surgical Outcomes of a Secondary
Macular Hole after Vitrectomy
Min Kim
9:25 a.m.  Discussion of Previous Five Papers  
9:29 a.m. Comparative Study of Peeled Internal Limiting Membrane (ILM) Reposition and
ILM Peeling in Idiopathic Macular Hole: A Randomized-Control Trial
Peiquan Zhao
9:38 a.m.  First Failed Macular Hole Surgery or Reopening of a Previously Closed Hole:
Do we Gain by Re-Operating? – A Systematic Review and Meta Analysis
Noemi Lois
9:47 a.m. Connecting the Surgeon to OCT Image Guidance for Vitreoretinal Surgery Cynthia Toth
9:56 a.m. Placing the Surgeon in the Center - Placing the Surgeon in the Center -
A Novel 3D Visualization Platform for Retina Surgery Providing Transparent
Display, Data Overlay and Guidance
Anat Loewenstein
10:05 a.m. Introduction and Presentation of the Paul Henkind Memorial Lecture and Award
- Sophie J. Bakri, MD
 
10:08 a.m. Paul Henkind Memorial Lecture and Award - Jose S. Pulido, MD, MS, MBA, MPH  
     
10:25 a.m. Break  
     
  SESSION X - Diabetic Macular Edema  
     
10:45 a.m. Müller Cells Activity is Restored and Retinal Inflammation Reduced by Subthreshold
Micropulse Laser Treatment of Human Diabetic Macular Edema
Edoardo Midena
10:49 a.m. OCT Angiography Detects Early Microvascular Changes after Subthreshold
Micropulse Laser in Diabetic Macular Edema
Stela Vujosevic
10:53 a.m. Two-year Outcomes of Ranibizumab Treatment for Diabetic Macular Edema.
Data from the Fight Retinal Blindness! Project
Daniel Barthelmes
10:57 a.m. Vision Threatening Complications in Patients with Diabetic Macular Edema:
A Post Hoc Analysis from the VISTA and VIVID Trials
Ivan Suner
11:01 a.m. Discussion of Previous Four Papers  
11:05 a.m. A 12-month Prospective Study to Evaluate the Efficacy of Treat and Extend Regimen (T&E)
of Intravitreal Aflibercept as a Second-Line Treatment for Diabetic Macular Edema (TADI Study)
Itay Chowers
11:14 a.m. Observation Versus Treatment in Diabetic Macular Edema with Very Good Visual Acuity
– The OBTAIN Study
Adrian Fung
11:23 a.m. Relationship between Change in Visual Acuity and Change in Retinal Thickness during
Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept,
Bevacizumab or Ranibizumab
Mathew MacCumber
11:27 a.m. Visual Acuity with Habitual Correction on an Early Treatment Diabetic Retinopathy
Study (ETDRS) Chart vs. Protocol Refraction on an Electronic ETDRS Chart in Eyes
with Diabetic Macular Edema
Susan Bressler
11:31 a.m. Long-Term Intraocular Pressure Outcomes in Patients Receiving the 0.2 ug/day Fluocinolone
Acetonide Intravitreal Implant
Daniel Roth
11:35 a.m. Discussion of Previous Three Papers  
11:39 a.m. Suprachoroidal CLS-TA Plus Aflibercept Compared to Aflibercept Monotherapy for
Diabetic Macular Edema: Results of the Randomized Phase 2 TYBEE Trial
Charles Wykoff
11:48 a.m. Dual Inhibition of Ang-2 and VEGF-A with Faricimab: Evidence for Increased Durability
from the BOULEVARD Phase 2 Trial for Diabetic Macular Edema
Caroline Baumal
     
  SESSION XI - Pediatric Retina and Inherited Retinal Diseases  
     
12:00 p.m. Fluorescein Angiography Findings in Infants Treated With Intravitreal Bevacizumab
for Retinopathy of Prematurity
G. Baker Hubbard, III
12:09 p.m. An Interesting Family with Achromatopsia J. Timothy Stout
12:18 p.m. Longitudinal Changes in Scotopic and Mesopic Macular Function as Assessed with
Microperimetry in Patients with Stargardt Disease – The SMART Study
Hendrik Scholl
12:27 p.m. Complement C5 Inhibition as a Potential Treatment for Autosomal Recessive Stargardt
Disease (STGD1): Design of a Clinical Trial Assessing a Novel Treatment and
Primary Outcome Measure
Christine Kay
12:36 p.m. Extracellular Matrix Disorders and Inherited Retinal Dystrophies Isabelle Meunier
12:40 p.m. RDH12 Disease: A Severe Central Retinal Degeneration with Relatively
Spared Rod Function
Tomas Aleman
12:44 p.m. Disease Stage Classification of Choroideremia for Clinical Treatment Trials
and Clinical Practice
Peter Francis
12:48 p.m. Optical Coherence Tomography Angiography Assessment of Neurovascular
Damage as Biomarker of Progression in Best Disease
Maurizio Battaglia Parodi
12:52 p.m. Discussion of Previous Four Papers  
1:00 p.m.  Introduction and Presentation of the Arnall Patz Medal – Gregory S. Hageman, MD, PhD  
1:03 p.m. Award Recipient – Mary Elizabeth Ruth Hartnett, MD, FACS, FARVO  
     
1:15 p.m. Adjourn  
     
Saturday, February 16, 2019 SESSION XII - Neuroprotection, Gene Therapy, Regenerative Medicine  
     
7:30 a.m VMD2 Promoter Shows Optimal Specificity and Expression of Protective
Rap1a in Retinal Pigment Epithelium
Mary Elizabeth Hartnett
7:39 a.m. A New Approach to Ocular Gene Therapy: Evaluation of Suprachoroidal
Administration of Non-Viral DNA Nanoparticles in a Rabbit Model
Szilard Kiss
7:48 a.m. Progress Toward Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa Edwin Stone
7:57 a.m. Change in Legal Blindness Status During the Phase 3 Voretigene Neparvovec-rzyl
Study in Biallelic RPE65 Mutation–Associated Inherited Retinal Disease
Julia Haller
8:06 a.m. Optogenetics for Vision Restoration Sai Chavala
8:15 a.m. Intraoperative Optical Coherence Tomographic Findings in Patients
Undergoing Ocular Gene Therapy Surgery
Andreas Lauer
8:19 a.m. Surgical Implantation and In-Vivo Degradation of Fibrin Scaffolds within the Subretinal Space Raymond Iezzi
8:23 a.m.  In-Vivo Imaging of Cone Photoreceptor Transplantation Mandeep Singh
8:27 a.m. Neuroprotective Role of Hexokinase 2 in Photoreceptor Survival Cagri Besirli,
8:31 a.m. Discussion of Previous Four Papers  
8:35 a.m. Introduction and Presentation of the W. Richard Green Lecture and Award
– Mary Elizabeth Ruth Hartnett, MD, FACS, FARVO
 
8:38 a.m. W. Richard Green Lecture and Award – Paul S. Bernstein, MD, PhD  
8:58 a.m. Introduction and Presentation of the Evangelos S. Gragoudas Lecture
and Award – Neil M. Bressler, MD
 
9:01 a.m. Evangelos S. Gragoudas Recipient Lecture and Award – Daniel Shu Wei Ting, MD, PhD  
9:05 a.m. Introduction and Presentation of the Lawrence J. Singerman Medal – Emily Y. Chew, MD  
9:08 a.m. Award Recipient – Maureen G. Maguire, PhD, FARVO  
     
  SESSION XIII - Oncology 2  
     
9:15 a.m. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable
Cancer Targets (MSK-IMPACT) of Retinoblastoma Tumors
Jasmine Francis
9:19 a.m. Discussion of Previous Paper  
9:21 a.m. Follow the Nevus: The Cost-Utility of Screening for Growth of Choroidal Nevi William Smiddy
9:30 a.m.  Small Choroidal Melanoma Managed by Plaque Radiotherapy in 1780 Cases:
Visual Outcome and Millimeter Incremental Risk for Metastasis
Carol Shields
9:39 a.m. Clinical Features and Survival Outcome of 1111 Patients with Choroidal
Metastasis Based on Primary Tumor Origin
Jerry Shields
9:48 a.m. Outcomes after Proton Irradiation for Patients Who are Eligible for
Investigational AU-011 Treatment
Evangelos Gragoudas
9:57 a.m. Aflibercept for Radiation Maculopathy (ARM Study): A Prospective, Randomized
Clinical Study with 2 year Outcome Analysis
Timothy Murray
     
10:10 a.m. Break  
     
  SESSION XIV - Other Macular Diseases  
     
10:30 a.m. Longitudinal Changes in Eyes with Hydroxychloroquine Retinal Toxicity Catherine Cukras
10:39 a.m. Topographic OCT Shows Limited Anatomic Recovery from Early
Hydroxychloroquine Retinopathy
Michael Marmor
10:48 a.m. Association Between Industry Payments and Scholarly Impact Amongst
Retina Specialists and Ophthalmologists
Ron Adelman
10:52 a.m. Anti-Enolase Drusen as a Subtype of Autoimmune Retinopathy Susumu Ishida
10:56 a.m. Genes Associated with the Clinical Characteristics of Central Serous
Chorioretinopathy
Akitaka Tsujikawa
11:00 a.m. Discussion of Previous Three Papers  
11:03 a.m. Chronic Obstructive Sleep Apnea and Central Serous Chorioretinopathy:
A Significant Association and Possible Mechanism
Steven Schwartz
11:12 a.m. Bruch’s Membrane and Myopic Axial Elongation Jost Jonas
11:21 a.m. Exploring Retinal Mechanisms in Myopia: Photopic Electroretinogram
Parameters and a Common Myopia Susceptibility Variant
Omar Mahroo
11:25 a.m. Digital Quantification of Metamorphopsia in Patients With Macular Disease:
A Pilot Study
Andrew Moshfeghi
11:29 a.m. Discussion of Previous Two Papers  
     
  SESSION XV - Retinal Venous Occlusive Disease  
     
11:32 a.m. Supernormal Flicker ERGs in Eyes with Central Retinal Vein Occlusion:
Clinical Characteristics, Prognosis, and Effects of Anti-VEGF Agent
Mineo Kondo
11:36 a.m. A Novel Contrast Sensitivity Testing Device as a New Clinical Endpoint for
Retinal Vein Occlusion
John Miller
11:40 a.m Discussion of Previous Two Papers  
11:42 a.m. Patient-Reported Visual Function Outcomes after Anti-VEGF Therapy for
Macular Edema due to CRVO or HRVO: Results from the SCORE2 Trial
Ingrid Scott
11:51 a.m. SD-OCT Predictors of Visual Outcomes after Ranibizumab Treatment for
Macular Edema due to Retinal Vein Occlusion in the SHORE Study
Glenn Yiu
12:00 p.m. Long Term Outcomes of Eyes with Macular Edema Secondary to CRVO
Treated with Intravitreal Bevacizumab. Real Life Experience of the
Pan American Collaborative Retina Study (PACORES) Group
Lihteh Wu
12:09 p.m. Re-packaging Bevacizumab in 2-mL Glass Vials for Prolonged Sterility, Stability and Bio-activity Michael Ip
     
  SESSION XVI - Uveitis  
     
12:20 p.m. Polymerase Chain Reaction in the Diagnosis of Toxoplasma Gondii
Chorioretinitis
Thomas Albini,
12:24 p.m. Collaborative Ocular Tuberculosis Study (COTS) Consensus Guidelines on
Initiating Antitubercular Therapy in Serpiginous Like Choroiditis
Vishali Gupta
12:28 p.m. Post-Surgical Versus Post-Intravitreal Injection Endophthalmitis:
Changing Patterns in Causative Flora
Matthew Simunovic
12:32 p.m. Discussion of Previous Three Papers  
12:34 p.m. Effect of Intravitreal Sirolimus on Visual Acuity in Subjects with Active Non-infectious
Uveitis of the Posterior Segment of the Eye: Results of the SAKURA Program
Brian Joodeph
12:43 p.m. Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone
Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs.
INTravitreal Corticosteroids for Uveitic Macular
Michael Altaweel
12:52 p.m. Suprachoroidally Injected CLS-TA Results in Rapid and Sustained Resolution of
Macular Edema in a Majority of Uveitis Patients: Results of the AZALEA,
DOGWOOD, and PEACHTREE Studies
Seenu Hariprasad
1:01 p.m. Suprachoroidal CLS-TA Improves Visual Acuity and Macular Edema in
Noninfectious Uveitis: Results of the Phase 3 PEACHTREE Study
Steven Yeh
     
1:04 p.m. Closing Remarks  
     
1:10 p.m. Adjourn  
Venue:
Hyatt Regency Coconut Point Resort and Spa

Address:
5001 Coconut Rd
FL 34134 Bonita Springs, USA
Scientific Organization:
The Macula Society
Event-Organizer:

The Macula Society
3401 Enterprise Parkway Suite 310
US - OH 44122 Cleveland, Ohio
Tel.: +1 216 839 4949
Fax: +1 216 831 8221

 
Mind:

 

Registration required. Please contact the organizer for further information.